

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

200.1133CON5

APPLICATION NO

10/700,906

LIST OF PRIOR ART CITED BY APPLICANT

APPLICANT

Benjamin OSHLACK et al.

FILING DATE

November 4, 2003

GROUP

1615

(Use several sheets if necessary)

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A01	Gorelick, David A, "The Rate Hypothesis and Agonist Substitution Approaches to Cocaine Abuse Treatment," <i>Advances in Pharmacology</i> , Vol 42., (1998).
A02	U.S. General Accounting Office "Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem <i>Report to Congressional Requesters</i> ", December 2003
A03	Becker, A.B. et al., Abstract: "Transdermal Buprenorphine: Abuse Potential Assessment in Non-Opioid-Dependent Volunteers," (2001).
A04	Farré, Magi et al., "Pharmacokinetic Considerations in Abuse Liability Evaluation," <i>British Journal of Addiction</i> (1991) 86, pp. 1601-1606
A05	Brookoff, Daniel, "Abuse Potential of Various Opioid Medications," <i>Journal of General Internal Medicine</i> , Vol. 8 (December), 1993, pp. 688-690
A06	Cami, Jordi et al., "Mechanisms of Disease: Drug Addiction," <i>New England Journal of Medicine</i> Vol. 349 No. 10 September 4, 2003, pp. 975-986
A07	Quinn, David I. et al., "Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users," <i>Clin. Pharmacokinet.</i> Vol. 33, No. 5 (1997), pp.344-400.
A08	Marsch, Lisa A. et al., "Effects of Infusion Rate of Intravenously Administered Morphine on Physiological, Psychomotor, and Self-Reported Measures in Humans," <i>The Journal of Pharmacology and Experimental Therapeutics</i> Vol. 299, No. 3, pp. 1056-1065, (2001).
A09	de Wit, Harriet et al., "Rate of Increase of Plasma Drug Level Influences Subjective Response in Humans," <i>Psychopharmacology</i> (1992) 107:352-358.
A10	de Wit, Harriet et al., "Subjective and Behavioral Effects of Diazepam Depend on its Rate of Onset," <i>Psychopharmacology</i> (1993) 112:324-330.
A11	Nelson, Richard A. et al., "Effect of Rate of Administration on Subjective and Physiological Effects of Intravenous Cocaine in Humans," <i>Drug and Alcohol Dependence</i> 82 (2006) pp. 19-24.
A12	Kollins, Scott H. et al., "Comparison of Acute Behavioral Effects of Sustained-Release and Immediate-Release Methylphenidate," <i>Experimental and Clinical Psychopharmacology</i> Vol. 6, No. 4 (1998) pp. 367-374.
A13	Roset, Pere N. et al., "Modulation of Rate of Onset and Intensity of Drug Effects Reduces Abuse Potential in Healthy Males," <i>Drug and Alcohol Dependence</i> 64 (2001) pp. 285-298.
A14	Parasrampur, Dolly A. et al., "Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans," <i>J. Clin. Pharmacol.</i> (2007) 47; pp. 1476-1488.
A15	Compton, Wilson M. et al., "Abuse of Prescription Drugs and the Risk of Addiction," <i>Drug and Alcohol Dependence</i> 83S (2006) S4-S7.
A16	Volkow, Nora D., "Stimulant Medications: How to Minimize Their Reinforcing Effects?," <i>Am J Psychiatry</i> 163:3, March 2006, pp. 359-361.
A17	Volkow, Nora D. et al., "Variables that Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD," <i>Am J Psychiatry</i> 160:11, November 2003, pp. 1909-1918
A18	Mathias, "Rate and Duration of Drug Activity Play Major Roles in Drug Abuse, Addiction, and Treatment," <i>NIDA Notes: NIDA-Supported Research</i> , Vol. 12, No. 2, March/April 1997
A19	Griffiths, Roland R. et al., Abstract: "Relative Abuse Liability of Diazepam and Oxazepam: Behavioral and Subjective Dose Effects," <i>Psychopharmacology (Berl)</i> 84 (1984)
A20	Mewaldt, S. P. et al., Abstract "The Behavioral Actions of Diazepam and Oxazepam are Similar," <i>Psychopharmacology</i> June 1986 Vol. 88, No. 2.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.